[SCHEDULE 13G] Cidara Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Paradigm BioCapital Advisors LP, its general partner, founder Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. jointly filed a Schedule 13G reporting passive ownership of 1,128,613 Cidara Therapeutics (CDTX) common shares as of 23 Jul 2025.

This holding equals 5.6 % of the 20,163,696 shares outstanding (per the issuer’s 25 Jun 2025 prospectus supplement), crossing the 5 % threshold that mandates disclosure. The Cayman-based Fund directly owns 994,177 shares (4.9 %), with the balance held in separately managed accounts advised by Paradigm. All shares are subject to sole voting and dispositive power; no shared power is reported.

The stake is filed under Rule 13d-1(c); the certification states the securities were not acquired to influence or change control. Signatures were executed on 30 Jul 2025 by authorized signatory David K. Kim. No additional agreements, transactions, or control intentions are disclosed.

Positive

• Paradigm BioCapital disclosed ownership of 5.6 % of CDTX, adding a specialized healthcare investor to the shareholder base.
• All reported shares are under sole voting and dispositive power, indicating clear ownership structure without complex arrangements.

Negative

• The stake is filed on Schedule 13G, signaling no intent to influence control, so immediate strategic benefits for other shareholders are limited.

Insights

Financial Analyst

TL;DR: Paradigm discloses a 5.6 % passive stake—incremental validation, limited strategic impact.

The filing signals that a life-sciences–focused hedge fund has accumulated a meaningful but non-controlling position in CDTX. A 5.6 % stake demonstrates confidence in the company’s prospects, yet the Schedule 13G (vs. 13D) and explicit certification confirm a passive intent, reducing expectations of activism. The bulk of shares (4.9 %) reside in the offshore fund, implying limited liquidity constraints. While institutional ownership can support share price stability, the position alone does not materially alter governance or capital structure. Overall impact to valuation is modest.

Corporate Governance Specialist

TL;DR: Ownership below control thresholds; governance implications minimal.

Because Paradigm’s stake is below 10 % and filed on a 13G, the group avoids filing obligations tied to intent to influence control (e.g., proxy contests). Sole voting power suggests no complicated voting arrangements. The absence of group formation or board-related provisions means current governance dynamics remain unchanged. Investors should monitor future filings for any conversion to a 13D, which would indicate a strategic shift.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cidara Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

171757206

(CUSIP Number)

07/23/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,128,613.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,128,613.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,128,613.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,128,613.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,128,613.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,128,613.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,128,613.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,128,613.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,128,613.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 994,177.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 994,177.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

994,177.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cidara Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6310 Nancy Ridge Drive Suite 101 San Diego, CA, 92121
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 767 Third Avenue, 17th Floor, New York, NY 10017.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 171757206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on July 23, 2025, the Date of Event which requires the filing of this Schedule 13G.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 20,163,696 shares of Common Stock outstanding on or about June 26, 2025 as reported by the Issuer in its Prospectus Supplement filed on June 25, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	07/30/2025

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	07/30/2025

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	07/30/2025

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	07/30/2025

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

FAQ

How many Cidara Therapeutics (CDTX) shares does Paradigm BioCapital own?

1,128,613 common shares as of 23 Jul 2025.

What percentage of CDTX’s outstanding stock is represented by Paradigm’s holding?

The filing lists 5.6 % of the 20.16 m shares outstanding.

Who are the reporting persons in the Schedule 13G?

Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd.

Is Paradigm seeking to influence control of Cidara Therapeutics?

No. The Schedule 13G includes a certification of passive intent under Rule 13d-1(c).

When was the Schedule 13G event date and filing date?

Event date: 23 Jul 2025; signatures dated 30 Jul 2025.